Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,239
Total Claims
$1.7M
Drug Cost
712
Beneficiaries
$2,429
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-96%
Opioid rate vs peers
0.1% vs 2.2% avg
+72%
Cost per patient vs peers
$2,429 vs $1,411 avg
+22%
Brand preference vs peers
13.0% vs 10.6% avg
Opioid Prescribing
0.1%
Opioid Rate
16
Opioid Claims
$74
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,343 claims · $1.4M
Generic: 15,744 claims · $325K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 172 | $158K |
| Apixaban | 147 | $107K |
| Semaglutide | 88 | $104K |
| Fluticasone/Umeclidin/Vilanter | 123 | $102K |
| Sitagliptin Phosphate | 67 | $82K |
| Insulin Glargine,hum.Rec.Anlog | 98 | $64K |
| Linaclotide | 80 | $55K |
| Umeclidinium Brm/Vilanterol Tr | 74 | $46K |
| Rifaximin | 13 | $41K |
| Sitagliptin Phos/Metformin Hcl | 31 | $41K |
| Tiotropium Bromide | 44 | $37K |
| Linagliptin | 45 | $35K |
| Fluticasone/Vilanterol | 38 | $33K |
| Rivaroxaban | 28 | $29K |
| Sacubitril/Valsartan | 21 | $28K |
Prescribing Profile
Patient Profile
70
Avg Age
61%
Female
1.54
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data